List of Excipients in Branded Drug LITHIUM CARBONATE

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Hikma Pharmaceuticals USA Inc	LITHIUM CARBONATE	lithium carbonate	0054-8528	CALCIUM STEARATE
Hikma Pharmaceuticals USA Inc	LITHIUM CARBONATE	lithium carbonate	0054-8528	CELLULOSE, MICROCRYSTALLINE
Hikma Pharmaceuticals USA Inc	LITHIUM CARBONATE	lithium carbonate	0054-8528	POVIDONE K30
Hikma Pharmaceuticals USA Inc	LITHIUM CARBONATE	lithium carbonate	0054-8528	SODIUM LAURYL SULFATE

Generic Drugs Containing LITHIUM CARBONATE

Company	Ingredient	NDC	Excipient
Hikma Pharmaceuticals USA Inc	lithium carbonate	0054-0020	FERRIC OXIDE YELLOW
Hikma Pharmaceuticals USA Inc	lithium carbonate	0054-0020	MAGNESIUM STEARATE
Hikma Pharmaceuticals USA Inc	lithium carbonate	0054-0020	POVIDONE
Hikma Pharmaceuticals USA Inc	lithium carbonate	0054-0020	SODIUM ALGINATE

What are the Most Frequently-Used Excipients in LITHIUM CARBONATE?

# Of NDCs	Excipient
22	ALCOHOL
1	ALGINIC ACID
22	AMMONIA
24	BUTYL ALCOHOL

Lithium Carbonate Excipient Strategy and Commercial Opportunities

Last updated: September 5, 2026

Lithium carbonate is an established generic active pharmaceutical ingredient with limited active-ingredient patent protection and substantial formulation opportunity. Commercial value is concentrated in extended-release tablets, dose-flexible immediate-release products, excipient-controlled dissolution, manufacturing reliability, and differentiated products for patients who need lower pill burden or improved tolerability.

The highest-value development strategy is an extended-release lithium carbonate product with tight control of dissolution, content uniformity, tablet robustness, moisture exposure, and dose flexibility. The principal regulatory risk is therapeutic-index management rather than molecular patent risk. Lithium concentrations must be monitored clinically, and formulation changes can affect exposure, tolerability, and switching behavior.

What is the regulatory and commercial status of lithium carbonate?

Lithium carbonate is an FDA-approved prescription drug used primarily for the treatment of bipolar disorder. FDA-approved products include immediate-release tablets and capsules and extended-release tablets. The drug is also supplied as a generic product under abbreviated new drug applications, or ANDAs, and under branded or authorized-generic names depending on the product and manufacturer.

Lithium carbonate has no meaningful modern composition-of-matter patent barrier. The molecule and core therapeutic use have been known for decades. Commercial protection therefore depends on:

• Extended-release formulation design
• Manufacturing process control
• Product-specific trademarks
• Device or packaging differentiation
• Contracting and supply reliability
• Regulatory execution under the ANDA pathway
• Potential formulation or method-of-use patents, where still enforceable

Lithium is not a biologic. Biosimilar competition does not apply. Generic competition is the relevant market risk.

Attribute	Lithium carbonate
Active ingredient	Lithium carbonate
Therapeutic area	Psychiatry; bipolar disorder
FDA pathway for generic entry	ANDA
Primary dosage forms	Immediate-release tablets, capsules, extended-release tablets
Main clinical risk	Narrow therapeutic index and lithium toxicity
Primary commercial differentiation	Release profile, dose flexibility, supply, tolerability, packaging
Biosimilar exposure	None
Active-ingredient patent risk	Low
Formulation and manufacturing risk	Moderate to high
Orange Book relevance	Product-specific listings and therapeutic-equivalence determinations

FDA-approved labeling emphasizes serum lithium monitoring, renal function, hydration, sodium balance, drug interactions, and toxicity symptoms. These requirements make consistent product performance commercially important even when the underlying compound is unprotected.

What excipients are used in lithium carbonate products?

The excipient strategy depends on whether the product is immediate release or extended release. FDA labeling and DailyMed records identify product-specific inactive ingredients, which vary by manufacturer and dosage form.[1,2]

Immediate-release lithium carbonate

Immediate-release tablets typically use excipients for compression, flow, binding, lubrication, coating, and appearance. Common functional categories include:

Excipient function	Typical materials	Strategic purpose
Diluent	Microcrystalline cellulose, lactose, dibasic calcium phosphate	Improve tablet size and compressibility
Binder	Povidone, pregelatinized starch, hydroxypropyl cellulose	Improve granule and tablet strength
Disintegrant	Crospovidone, croscarmellose sodium, sodium starch glycolate	Promote tablet breakup
Lubricant	Magnesium stearate, stearic acid	Control ejection and tooling
Glidant	Colloidal silicon dioxide	Improve powder flow
Film coating	Hypromellose, polyethylene glycol, titanium dioxide, colorants	Improve handling, identification, and swallowability

Lithium carbonate has a relatively high inorganic salt load. Formulators must evaluate blend density, segregation, particle-size distribution, and tablet weight. Excessive use of low-density excipients can produce large tablets and create patient acceptability problems, especially at higher daily doses.

The principal immediate-release objective is rapid and reproducible dissolution without excessive sensitivity to compression force. Over-lubrication with hydrophobic materials such as magnesium stearate can slow wetting and dissolution. This risk is manageable but should be tested across lubricant concentration, blending time, compression force, and scale-up conditions.

Extended-release lithium carbonate

Extended-release products use excipients to regulate water penetration, gel formation, diffusion, erosion, or matrix porosity. Common platform materials include:

• Hypromellose, especially high-viscosity grades
• Hydroxypropyl cellulose
• Ethylcellulose
• Methacrylate copolymers
• Polyethylene oxide
• Microcrystalline cellulose
• Colloidal silicon dioxide
• Stearic acid or magnesium stearate
• Film-coating polymers and plasticizers

A hydrophilic matrix based on hypromellose is usually the most accessible development platform. Water penetrates the tablet, the polymer hydrates, and the gel layer controls lithium carbonate release. The formulation must maintain release performance across pH conditions and gastrointestinal transit conditions.

A hydrophobic matrix or coated multiparticulate system can provide stronger control over release but generally adds process complexity, manufacturing cost, and scale-up risk. Multiparticulates may support more flexible dose combinations, but lithium carbonate loading, particle coating uniformity, and capsule-fill variability require close control.

What excipient strategy is best for lithium carbonate extended-release tablets?

A commercially practical strategy is a robust hydrophilic matrix tablet with a moderate excipient count and a release profile demonstrated against the reference product. Development should focus on the following variables:

1. Lithium carbonate particle size and surface area.
2. Hypromellose grade and concentration.
3. Granulation endpoint and residual moisture.
4. Compression force and tablet porosity.
5. Lubricant concentration and blending time.
6. Tablet coating weight gain.
7. Dissolution performance across pH and agitation conditions.
8. Food-effect behavior.
9. Stability under humidity and temperature stress.

Lithium carbonate is sparingly soluble in water compared with many conventional salts. Particle size can influence dissolution, but an excessively fine API may worsen flow, electrostatic behavior, and segregation. A controlled particle-size specification is preferable to relying on a single nominal milling condition.

The excipient system should not be selected only for initial dissolution. The release profile must remain stable after storage, because polymer hydration behavior, tablet porosity, and moisture uptake can change over time. Moisture-barrier packaging may be more commercially valuable than a complex excipient innovation.

Formulation screening priorities

Development variable	Main risk	Recommended control
API particle size	Dissolution and blend variability	Narrow particle-size distribution
Polymer viscosity	Release-rate drift	Supplier qualification and incoming testing
Polymer concentration	Dose dumping or incomplete release	Design-of-experiments screening
Lubrication	Slow dissolution and weak tablets	Limit blend time and lubricant level
Compression force	Porosity and release changes	Defined operating range
Moisture	Stability and dissolution changes	Controlled granulation and barrier packaging
Coating	Swallowability and identification	Functional coating specification
pH sensitivity	Variable release in vivo	Multi-pH dissolution testing

FDA guidance for ANDA products recommends comparative dissolution testing and, where applicable, bioequivalence studies that account for the dosage form and release characteristics.[3] For a narrow-therapeutic-index product, the development program should use conservative acceptance criteria and characterize both average exposure and variability.

What FDA regulatory issues affect lithium carbonate excipient selection?

Lithium carbonate is not generally regulated as a biologic or complex drug product. The central FDA issue is therapeutic equivalence and consistency. The product must meet applicable quality, dissolution, stability, and bioequivalence requirements under the ANDA framework.

FDA identifies narrow therapeutic index drugs as products for which relatively small differences in dose or blood concentration can produce serious therapeutic failure or adverse reactions. Lithium products are commonly managed clinically as narrow-therapeutic-index medicines because toxicity and efficacy are closely related to serum concentration.[4]

Excipient changes can affect:

• Peak and trough lithium concentrations
• Time to peak concentration
• Exposure variability
• Food-related absorption
• Patient switching experience
• The interpretation of serum lithium monitoring

For an extended-release product, an excipient change that appears minor from a manufacturing perspective can materially change the release profile. This makes post-approval change control important. The manufacturer should define formulation-critical material attributes and process parameters before commercial launch.

The FDA Inactive Ingredient Database can support excipient precedent and maximum-potency analysis, but prior use in another product does not eliminate the need to establish product performance.[5] Novel excipients would increase development and regulatory burden and are rarely necessary for lithium carbonate.

What is the Orange Book status of lithium carbonate?

The Orange Book is relevant to lithium carbonate through listed products, therapeutic equivalence codes, patents, exclusivity, and reference standards. Lithium carbonate generic entry generally relies on an ANDA referencing an FDA-designated reference listed drug.

The practical Orange Book position is:

• No current composition-of-matter exclusivity protects lithium carbonate.
• Generic products are the principal competitive supply.
• Any listed patent must be assessed by product, dosage form, and reference product.
• Immediate-release and extended-release products should be analyzed separately.
• Orange Book patent listings do not eliminate non-patent regulatory barriers such as bioequivalence, manufacturing capacity, or supply qualification.

Because Orange Book listings can change with product discontinuations, patent delistings, and new ANDA approvals, an investment or launch decision should use the latest FDA Orange Book edition and product-specific records.[6]

When does lithium carbonate lose exclusivity?

Lithium carbonate lost practical market exclusivity long ago. The relevant question is no longer loss of original exclusivity but whether any formulation-specific patents or regulatory exclusivities remain attached to a particular product.

Protection type	Commercial relevance
Composition-of-matter patent	Expired or commercially irrelevant
Original therapeutic-use exclusivity	Expired
New chemical entity exclusivity	Not relevant to current generic entry
Pediatric exclusivity	Not a principal current barrier
Formulation patent	Possible, but product-specific and generally time-limited
Method-of-use patent	Possible, but usually narrower than the product market
Orphan exclusivity	Not a general barrier for bipolar-disorder lithium products
Biosimilar exclusivity	Not applicable

Potential entrants should distinguish product-level patent protection from the absence of an active-ingredient barrier. A formulation patent could delay one product while leaving other lithium carbonate presentations open to competition.

Are there Paragraph IV challenges for lithium carbonate?

Paragraph IV certification is theoretically available for an ANDA applicant challenging a listed patent. In practice, the commercial importance depends on whether the reference product has an unexpired, Orange Book-listed patent covering the relevant dosage form.

For legacy lithium carbonate products, the more likely entry pathway is a Paragraph III certification, a certification that the patent will expire before commercial launch, or a filing against a product with no relevant listed patent. A Paragraph IV strategy would have value only if:

• The target reference product has an unexpired listed patent.
• The proposed product can avoid the patent claims or establish invalidity.
• The expected market share justifies litigation costs.
• The applicant can sustain launch timing and supply investment.

Patent litigation risk is therefore lower than regulatory and manufacturing risk for most lithium carbonate opportunities. Exact Paragraph IV exposure must be confirmed against the current Orange Book and court docket records for the selected reference product.

What patent litigation affects lithium carbonate?

Lithium carbonate does not have the litigation profile of newer psychiatric drugs protected by active composition, combination, or delivery patents. The likely disputes involve:

• Extended-release matrix technology
• Coated dosage forms
• Manufacturing processes
• Infringement allegations against a branded extended-release product
• ANDA approval timing
• Product labeling and method-of-use claims

Patent strength is generally weak for the active ingredient and variable for formulation claims. A broad patent covering lithium carbonate itself would face substantial validity pressure because of the compound’s long history. Narrower formulation claims can be stronger if they define measurable release parameters, specific polymer systems, or manufacturing conditions that are difficult to design around.

A commercial diligence review should examine:

1. Current Orange Book patent listings.
2. USPTO assignment and maintenance records.
3. Federal court docket history.
4. Patent family members in the United States, Europe, Canada, Japan, and other target markets.
5. Expired patents that still disclose useful formulation technology.
6. Freedom-to-operate risks involving polymer matrices and coating systems.

What commercial opportunities exist in lithium carbonate excipients?

The strongest opportunities are product and supply-chain opportunities rather than new-molecule opportunities.

1. Extended-release generic tablets

Extended-release lithium carbonate can command strategic value through reduced dosing frequency, better adherence, and differentiated pharmacy positioning. The product must match or closely approximate the reference release behavior.

2. Dose-flexible presentations

A portfolio containing 150 mg, 300 mg, and 450 mg strengths can support titration and reduce tablet splitting. Dose flexibility is useful because lithium dosing is individualized around serum concentrations and renal function.

3. Improved swallowability

Large tablets and frequent dosing can impair adherence. Film coating, tablet-size reduction, capsule-based delivery, and high-load compression platforms may create commercial differentiation without relying on a novel excipient.

4. Moisture-protective packaging

Aluminum-aluminum blister packaging, high-barrier bottles, desiccant systems, and improved child-resistant closures can reduce stability risk. Packaging is often a more defensible commercial investment than an unproven excipient.

5. Contract manufacturing

Lithium carbonate products are suitable for manufacturers with controlled-release tablet capability, high-containment powder handling, validated dissolution testing, and flexible packaging operations. Reliable supply can support licensing or private-label agreements.

6. International generic expansion

The United States, European Union, Canada, Australia, Japan, and selected emerging markets have established demand for lithium products. Regulatory requirements differ, but the core technical opportunity remains the same: consistent release, stability, and clinically acceptable switching.

Geographic coverage and regulatory complexity

Market	Main regulatory pathway	Commercial consideration
United States	ANDA	Orange Book, therapeutic equivalence, Paragraph IV risk
European Union	National or decentralized generic application	Reference-product selection and bioequivalence
Canada	Abbreviated New Drug Submission	Product monograph and comparative studies
Australia	Generic registration	Quality and bioequivalence documentation
Japan	Generic application	Local regulatory and dissolution requirements
Emerging markets	National generic pathways	Price pressure and supply reliability

How does lithium carbonate compare with competing psychiatric drugs?

Lithium carbonate competes with anticonvulsant mood stabilizers, atypical antipsychotics, and other bipolar-disorder therapies. Its commercial position differs from newer branded products.

Product class	Patent intensity	Excipient opportunity	Main commercial risk
Lithium carbonate	Low	Moderate	Price erosion and monitoring burden
Valproate products	Low to moderate	Moderate	Generic competition and safety restrictions
Lamotrigine	Low	Moderate	Multiple generic suppliers
Atypical antipsychotics	Variable to high	High for long-acting and modified-release products	Patent and indication litigation
Long-acting injectables	High technical complexity	High	Manufacturing and device barriers

Lithium remains strategically relevant because it has long clinical use and a distinct role in bipolar disorder. Its weakness is low unit pricing and high monitoring requirements. A supplier must win through cost, reliable availability, product quality, and pharmacy access rather than premium pricing alone.

What generic launch scenarios exist for lithium carbonate?

Low-risk launch

An applicant launches an immediate-release tablet against an unprotected reference product. The principal requirements are bioequivalence, manufacturing scale, and competitive pricing.

Moderate-risk launch

An applicant develops an extended-release tablet with a hydrophilic matrix. The main risks are comparative dissolution, food effect, formulation scale-up, and substitution acceptance.

Higher-value launch

A company develops multiple strengths, high-barrier packaging, and a reliable supply agreement with a pharmacy or health-system buyer. The product may achieve better commercial durability despite generic pricing.

Litigation-led launch

An applicant challenges a still-listed formulation patent under Paragraph IV. This scenario is less common for legacy lithium products and requires a meaningful addressable market to justify legal expense.

What manufacturing and intellectual-property barriers matter most?

The principal barriers are operational:

• API particle-size control
• Segregation during blending
• High tablet weight
• Compression defects
• Dissolution drift after scale-up
• Moisture sensitivity
• Polymer supply variability
• Cleaning validation
• Content-uniformity control
• Packaging qualification
• Stability under accelerated conditions

The most valuable intellectual property is likely to protect a reproducible process or a technically difficult release profile. A patent strategy could cover:

• Specific polymer ratios
• Defined dissolution windows
• Controlled porosity
• Multiparticulate coating architecture
• Moisture-protective packaging combinations
• Manufacturing conditions that improve release consistency

Such claims must be drafted with careful attention to prior art. Broad claims directed to lithium carbonate extended-release tablets are vulnerable because the technology has been widely disclosed.

What revenue exposure exists in lithium carbonate?

Lithium carbonate is generally a low-price, high-volume generic opportunity rather than a high-margin specialty pharmaceutical. Revenue depends on:

• Number of approved suppliers
• Retail and institutional purchasing contracts
• Dosage-form mix
• Market share after substitution
• Shortage history and supply reliability
• Availability of all clinically useful strengths
• Reimbursement and generic pricing

Extended-release products can have higher strategic value than immediate-release products because fewer suppliers may compete in the same presentation and formulation complexity is greater. The opportunity is strongest where a manufacturer can combine regulatory execution with dependable supply and a differentiated packaging or dose-strength portfolio.

Key Takeaways

• Lithium carbonate has little meaningful active-ingredient patent protection.
• Generic and extended-release formulation competition is the central market dynamic.
• A hydrophilic polymer matrix is the most practical starting platform for extended-release development.
• Excipient selection must protect dissolution consistency, not merely tablet manufacture.
• Lithium’s narrow therapeutic index increases the importance of formulation comparability and change control.
• FDA regulatory risk is more significant than biosimilar or composition-of-matter patent risk.
• Immediate-release products offer simpler entry but face stronger price competition.
• Extended-release tablets, dose flexibility, packaging, and supply reliability offer the clearest commercial opportunities.
• Current Orange Book listings and litigation records must be checked for the selected reference product before launch or licensing decisions.
• The strongest defensible position is usually a combination of formulation know-how, manufacturing control, regulatory approval, and dependable supply.

Frequently Asked Questions

Can lithium carbonate use novel excipients?

Yes, but a novel excipient is usually unnecessary. Established excipients such as hypromellose, microcrystalline cellulose, povidone, and standard coating polymers provide sufficient formulation flexibility for most lithium carbonate products.

Is lithium carbonate suitable for an orally disintegrating tablet?

It is technically possible, but the high dose burden and salt taste create significant formulation challenges. An orally disintegrating presentation would require taste masking, rapid disintegration, acceptable tablet size, and careful control of lithium exposure.

Can lithium carbonate be formulated as a liquid?

Yes. An oral solution or suspension may improve dose flexibility, but chemical stability, taste, sedimentation, microbial control, and dosing accuracy become central development issues. A liquid product would not automatically have a commercial advantage over low-cost tablets.

Does lithium carbonate require special packaging?

Barrier packaging is commercially advisable, particularly for products sensitive to moisture-related changes in tablet performance. Packaging should be selected with stability data rather than treated as a generic container-closure decision.

Is an extended-release lithium carbonate product automatically substitutable for an immediate-release product?

No. Release characteristics, dosing frequency, bioequivalence, labeling, and FDA therapeutic-equivalence determinations control substitution. Immediate-release and extended-release products should not be treated as interchangeable solely because they contain the same active ingredient.

References

1. DailyMed. (n.d.). Lithium carbonate product labeling. U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/

2. U.S. Food and Drug Administration. (n.d.). Lithium carbonate extended-release tablets: Prescribing information. FDA. https://www.accessdata.fda.gov/

3. U.S. Food and Drug Administration. (2003). Bioavailability and bioequivalence studies for orally administered drug products: General considerations. FDA.

4. U.S. Food and Drug Administration. (2011). Guidance for industry: Bioequivalence recommendations for specific products. FDA.

5. U.S. Food and Drug Administration. (n.d.). Inactive Ingredient Database. FDA. https://www.accessdata.fda.gov/scripts/cder/iig/index.cfm

6. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations, commonly known as the Orange Book. FDA. https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book-data-files

7. United States Pharmacopeial Convention. (2024). Lithium carbonate monograph. In United States Pharmacopeia and National Formulary. USP.